Recent Advances and Future Prospects in Immune Checkpoint (ICI)-Based Combination Therapy for Advanced HCC

Recent Advances and Future Prospects in Immune Checkpoint (ICI)-Based Combination Therapy for Advanced HCC

Advanced, unresectable hepatocellular carcinoma has a dismal outcome. Multiple immune checkpoint inhibitors (ICIs) targeting the programmed-cell death 1 pathway (PD-1/L1) have been approved for the treatment of advanced HCC. However, outcomes remain undesirable and unpredictable on a patient-to-pati...

Full description

Bibliographic Details
Main Authors: Yawen Dong, Jeffrey Sum Lung Wong, Ryohichi Sugimura, Ka-On Lam, Bryan Li, Gerry Gin Wai Kwok, Roland Leung, Joanne Wing Yan Chiu, Tan To Cheung, Thomas Yau
Format: Article
Language:English
Published: MDPI AG 2021-04-01
Series:Cancers
Subjects:
hepatocellular carcinoma
biomarker
checkpoint inhibitors
combination therapy
targeted therapy
precision medicine
Online Access:https://www.mdpi.com/2072-6694/13/8/1949

Internet

https://www.mdpi.com/2072-6694/13/8/1949

Similar Items